新型脂糖肽类抗生素Telavancin的研究进展
摘要
介绍了新型脂糖肽类抗生素Telavancin的研发动态、药物化学、药理作用和临床研究等相关的内容。
出处
《安徽医药》
CAS
2008年第12期1124-1127,共4页
Anhui Medical and Pharmaceutical Journal
参考文献15
-
1No authors listed. Telavancin : TD 6424, TD - 6424 [ J ]. Drugs RD, 2006,7(6) :384-8.
-
2Pace JL, Krause K, Johnston D, et al. In vitro activity of TD -6424 against Staphylococcus aureus [ .[~. Antimicrob Agents Chemother, 2003,47:3602 - 4.
-
3Pace JL,Judice JK. Telavancin (Theravance) [ J]. Curt Opin Invesrig Drugs ,2005,6 ( 2 ) :216 - 25.
-
4Leadbetter MR,Adams SM. Hydrophobic vancomycin derivatives with improved ADME properties : discovery of telavancin ( TD - 6424 ) [ J ]. J Antibiot (Tokyo) ,2004,57 (5) :326 - 36.
-
5Deborah LH, Ray C, Dmitri VD, et al. Humphrey, Telavancin, a Multifunctional Lipoglycopeptide . Disrupts both CellWall Synthesis and Cell Membrane Integrity in Methicillin-Resistant Staphylococcus aureus[ J ]. Antimicrobial Agents and Chemotherapy, 2005,49 ( 3 ) : 1127 -34.
-
6Armin S, Peter G, Fernando A, et al. Efficacy of Telavancin against Penicillin-Resistant Pneumococci and Staphylococcus aureus in a Rabbit Meningitis Model and Determination of Kinetic Parameters [ J ]. Antimicrobial Agents and Chemotherapy,2006,50 ( 2 ) :770 - 3.
-
7Noe R, Robert S, Kone' K. Efficacy of Telavancin ( TD-6424 ) , a Rapidly Bactericidal Lipoglycopeptide with Multiple Mechanisms of Action, in a Murine Model of Pneumonia Induced by Methicillin-Resistant Staphylococcus aureus [ J ]. American Society for Microbiology,2005,49 ( 10 ) :4344 - 6.
-
8Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid ( PNU - 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia : a randomized, double-blind, multicenter study[ J]. Clin Infect Dis,2001,32:402 - 12.
-
9Ellie JC, Goldstein, Citron DM, Merriam V, et al. In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin ( TD-6424 ), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents a- gainst Anaerobic Gram-Positive Species and Corynebacterium spp [ J ]. Antimicrobial Agents and Chemotherapy ,2004,48 (6) :2149 - 52.
-
10Giglione C, Meinnel T. The situation on antimierobial agents and chemotherapy in 2002 : highlights of the 42nd ICAAC [ J ]. Expert Opin, Ther, Targets,2002,6:691 - 7.
-
1Vibativ~在欧洲获批[J].中国新药杂志,2011,20(22):2272-2272.
-
2陆义（摘）.Astellas公司获得telavancin[J].国外药讯,2006(3):30-30.
-
3申请新适应证和进入Ⅱ／Ⅲ期临床研究的药物[J].药学进展,2009,33(6):285-285.
-
4金伟秋（摘）.Telavancin申请美国NDA[J].国外药讯,2007(5):26-27.
-
5Saravolatz LD,Stein GE,Johnson LB,秦晓华,王明贵.替拉万星(telavancin):一种新型脂糖肽类抗菌药[J].中国感染与化疗杂志,2011,11(4):313-313.
-
6Telavancin有效对抗革兰氏阳性菌的复杂感染[J].传染病网络动态,2005(7):4-4.
-
7新的注射用杀菌抗生素telavancin美国获批[J].中国处方药,2009(10):50-50.
-
8梁玉华,冯文化.脂糖肽抗生素Telavancin的合成工艺改进[J].合成化学,2011,19(4):550-553. 被引量：4
-
9杨娜,程卯生.Telavancin hydrochloride[J].中国药物化学杂志,2010,20(2):158-158.
-
10抗感染药——Astellas公司再次向欧盟提出telavancin的申请[J].国外药讯,2010(1):18-18.
